



# Grand Rounds

RSS (Regularly Scheduled Series)

Presented by

**Yale School of Medicine**

**Department of Obstetrics, Gynecology & Reproductive Sciences**

## Integrating Genomics into Endometrial Cancer Clinical Practice; Updates in Targeted Treatments for Uterine Serous Carcinoma



### Alessandro Santin, MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

**March 5, 2020 • 4:00-5:00 pm**  
**Brady Auditorium, 310 Cedar St**

*There is no corporate support for this activity.*

*Course Director/Host: Lubna Pal, MBBS, FRCOG, MS, FACOG*

#### **ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **TARGET AUDIENCE:**

ObGyn attending physicians, house staff/fellows, medical students, nurses, PA's, community Ob/Gyn's, residents, midwives, nurses and researchers.

#### **NEEDS ASSESSMENT:**

The role of genetic analysis in cancer is rapidly expanding and is complex and challenging for pathologists and clinicians to understand and implement such testing in a meaningful and useful manner. Based on the Cancer Genome Atlas, pragmatic molecular classifiers that identify four prognostically distinct molecular subgroups of endometrial carcinoma have been developed. The evolution of genomic classification in endometrial cancer, how to optimally integrate molecular classification into current standard of care, and therapeutic strategies in this setting will be discussed in this lecture. Specifically, appraisal of recent Phase II clinical trials that have demonstrated the benefits of Her2/NEU targeted therapies in the management of recurrent or advanced endometrial carcinoma with specific molecular classifiers will be reviewed.

#### **LEARNING OBJECTIVES:**

At the end of this presentation, attendees will be able to:

1. Discuss the evolution of genomic classification in endometrial cancer;
2. Optimally integrate molecular classification into current standard of care; and
3. Discuss the role of her2/NEU as novel therapeutic target in uterine serous carcinoma.

#### **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

#### **FACULTY DISCLOSURES:**

**Course Director: Lubna Pal, MD**

Flo Health, Consultant  
AMAG Advisory Board, Member  
GLG, Consultant  
Abbott Advisory Board, Member

**Speaker: Alessandro Santin, MD**

Merck Pharmaceuticals, Consulting/Advisory Role  
PUMA Inc. Pharmaceuticals, Consulting/Advisory Role

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.